DDInter1018 DDInter1676
Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its possible use as a laxative for the treatment of chronic constipation did not occur until the 1960s and its first clinical use for treating PSE was not until 1966. Nevertheless, although lactulose received formal FDA approval in 1977 and has since become a readily available generic and brand-name non-prescription medication listed on the World Health Organization's List of Essential Medicines as one of the most effective and safe medicines employed in a health system, data regarding its optimal place in therapy is often ambiguous. Especially considering the use of lactulose as a laxative is typically only considered after lifestyle and dietary modifications fail and the
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Lactulose {u} (Compound) resembles {v} (Compound) Kanamycin
Lactulose {u} (Compound) resembles {v} (Compound) Acarbose
Lactulose {u} (Compound) is included by {v} (Pharmacologic Class) Acidifying Activity
Lactulose {u} (Compound) causes {v} (Side Effect) Abdominal discomfort
Lactulose {u} may cause a minor interaction that can limit clinical effects when taken with {v} Neomycin
Lactulose {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Perflutren
Lactulose {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ofloxacin
Lactulose (Compound) resembles Kanamycin (Compound)
Lactulose (Compound) resembles Acarbose (Compound)
Lactulose (Compound) is included by Acidifying Activity (Pharmacologic Class)
Lactulose (Compound) causes Abdominal discomfort (Side Effect)
Lactulose may cause a minor interaction that can limit clinical effects when taken with Neomycin
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Perflutren
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin